Educational resources

This section includes resources developed by Guidelines, including algorithms, eLearning modules, medicines appraisal cards, supplements, and videos.

Videos

View more videos

Webinars

Screen Shot 2019-10-22 at 11.25.04

Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)

2019-10-22T10:56:00+01:00Commissioned by Takeda UK Ltd

This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.

Algorithms

20190820 Renal impairment Algorithm_PI update

Non-vitamin K oral anticoagulant options for patients with non-valvular atrial fibrillation and renal impairment

2019-01-10T12:34:00+00:00Commissioned by Bayer

Medicines appraisal cards

Medicines appraisal cards have been developed for the Guidelines audience to announce new recommendations from the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG).

Image of first page of NICE TA card

NICE Technology Appraisal 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease

2019-10-24T10:32:00+01:00Commissioned by Bayer

The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.

Xeljanz SMC 30:07

Tofacitinib▼ (Xeljanz®) SMC2122, SMC1298/18, SMC2116

2019-04-24T07:29:00+01:00Commissioned by Pfizer Limited

Information intended for healthcare professionals only.

Xeljanz TA pic

Tofacitinib▼ (Xeljanz®) NICE TA547, TA480, TA543

2019-04-24T07:26:00+01:00Commissioned by Pfizer Limited

Information intended for healthcare professionals only.

Xarelto SMC card

Xarelto® ▼ (rivaroxaban) SMC2128

2019-03-14T13:25:00+00:00Commissioned by Bayer

The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed this card for technical accuracy and regulatory compliance. The SMC has reviewed this card for technical accuracy and permission request only. The SMC were not involved in the production of this card.

Final version_Ozempic AWMSG card PI update

AWMSG card: Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼)

2019-03-11T09:17:00+00:00Funded by Novo Nordisk Limited

Information intended for healthcare professionals only.

Final version_Ozempic SMC card PI update

Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼) SMC No. (2092)

2019-02-11T12:51:00+00:00Funded by Novo Nordisk Limited

Information intended for healthcare professionals only.

Supplements

Guidelines supplements are written by experts and typically discuss a piece of national guidance, pulling out key learning points for GPs.

Index image

Hormone replacement therapy (HRT) shortage: switching to Femoston® (estradiol/dydrogesterone) from an alternative combination oral or transdermal HRT

2019-12-19T08:31:00+00:00Commissioned by Mylan


Validate Accessibility